Palisade Bio (PALI) Total Non-Current Liabilities (2012 - 2026)
Palisade Bio (PALI) reported Total Non-Current Liabilities of $5.9 million for Q1 2026, up 106.2% year-over-year from $2.9 million in Q1 2025, and up 20.18% on a QoQ basis from $4.9 million in Q4 2025.
Palisade Bio (PALI) has 15 years of Total Non-Current Liabilities data on file, last reported at $5.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 106.2% year-over-year to $5.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 million (up 106.2% YoY) and the FY2025 annual result came in at $4.9 million, up 44.69% from the prior year.
- Total Non-Current Liabilities advanced to $5.9 million in Q1 2026 per PALI's latest filing, from $4.9 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.9 million in Q1 2026 and bottomed at $1.5 million in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $2.9 million (2024), against an average of $3.2 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities fell 20.41%; it then jumped 106.2% in 2026.
- Tracing PALI's Total Non-Current Liabilities over 5 years: stood at $3.3 million in 2022, then decreased by 18.45% to $2.7 million in 2023, then grew by 26.51% to $3.4 million in 2024, then surged by 44.69% to $4.9 million in 2025, then gained by 20.18% to $5.9 million in 2026.
- Per Business Quant, the three latest PALI Total Non-Current Liabilities figures stand at $5.9 million (Q1 2026), $4.9 million (Q4 2025), and $3.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | 5.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.89 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 2.68 Mn |
| Sep 30, 2023 | 2.77 Mn |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 3.44 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 1.86 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.92 Mn |
| Jun 30, 2021 | 3.87 Mn |
| Mar 31, 2021 | 1.01 Mn |
| Dec 31, 2020 | 8.29 Mn |
| Sep 30, 2020 | 1.00 Mn |
| Jun 30, 2020 | 804,746.00 |
| Mar 31, 2020 | 1.32 Mn |
| Dec 31, 2019 | 1.37 Mn |
| Sep 30, 2019 | 1.73 Mn |
| Jun 30, 2019 | 1.07 Mn |
| Mar 31, 2019 | 1.21 Mn |
| Dec 31, 2018 | 1.05 Mn |
| Sep 30, 2018 | 1.19 Mn |
| Jun 30, 2018 | 774,271.00 |
| Mar 31, 2018 | 4.94 Mn |
| Dec 31, 2017 | 1.52 Mn |
| Sep 30, 2017 | 4.62 Mn |
| Jun 30, 2017 | 2.31 Mn |
| Mar 31, 2017 | 5.06 Mn |
| Dec 31, 2016 | 7.35 Mn |
| Sep 30, 2016 | 7.87 Mn |
| Jun 30, 2016 | 12.44 Mn |
| Mar 31, 2016 | 10.17 Mn |
| Dec 31, 2015 | 9.81 Mn |
| Sep 30, 2015 | 12.10 Mn |
| Jun 30, 2015 | 11.72 Mn |
| Mar 31, 2015 | 11.29 Mn |
| Dec 31, 2014 | 12.07 Mn |
| Sep 30, 2014 | 8.32 Mn |
| Jun 30, 2014 | 8.41 Mn |
| Mar 31, 2014 | 8.87 Mn |
| Dec 31, 2013 | 10.87 Mn |
| Sep 30, 2013 | 10.81 Mn |
| Jun 30, 2013 | 9.37 Mn |
| Mar 31, 2013 | 9.70 Mn |
| Dec 31, 2012 | 1.76 Mn |